Animal safety studies can miss a dangerous human response. In the 2006 TGN1412 trial, all six healthy volunteers developed life-threatening reactions even though preclinical testing had appeared adequate. That failure does not mean animal studies are useless or that animal testing alone caused every trial injury. It shows why results from animals must be interpreted alongside human-relevant evidence, careful dose selection, and safeguards for first-in-human studies.
How can animal testing fail to predict what a drug will do in people?
Animal studies can reveal important hazards, but they are models of human biology, not exact copies of it. The U.S. Food and Drug Administration’s April 2026 report identifies differences in disease state, drug targets, pharmacokinetics, metabolism, and idiosyncratic or off-target responses as reasons animal results may not forecast every human reaction.
As an Amazon Associate I earn from qualifying purchases.
The failure can be biological: a drug may interact differently with human cells than with cells from another species. It can also involve how a study is interpreted or translated into a human trial, including dose choice, monitoring, or trial conduct. A serious event after animal testing does not, by itself, establish which of these factors caused it.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteThe FDA’s April 2026 report says that over 90% of drugs that appear safe in animals fail to receive FDA approval, attributing the principal reasons to safety and/or efficacy issues that become apparent in human trials. The figure, which the report draws from a 2023 narrative review, is not a measure of how often animal studies are wrong: failure to gain approval can reflect lack of efficacy as well as safety problems.
#1 Best Overall
- FMCSA regulations book includes Parts 40, 380, 382, 383, 387, 390-397, 399 and Appendix G of the FMCSRs. Also covers the ELD rules found in Part 395, Subpart B.
- FMCSA handbook includes a driver receipt page. Helps in documenting that the carrier has supplied drivers with proper regulatory information.
- FMCSR handbook is reprinted every month, ensuring access to up-to-date Federal Motor Carrier Safety Regulations. You will receive the latest edition when you order.
- FMCSR handbook contains regulatory info on a wide range of fleet safety topics: alcohol & drug testing; CDL standards; financial responsibility for motor carriers; driver qualification; safe operation of commercial motor vehicles; hours of service; vehicle inspection, repair & maintenance; transporting hazardous materials; texting ban; employee safety & health standards; minimum periodic inspection standards; & much more.
- Federal Motor Carrier Safety Regulations FMCSR Pocketbook is softbound (perfect bound) with 624 pages and measures 5" x 7".
What do the documented cases show?
| Drug and type | Human outcome and setting | What preclinical or retrospective evidence showed | Evidence and main lesson |
|---|---|---|---|
| TGN1412 (theralizumab), a CD28 superagonist antibody | In a 2006 first-in-human trial, all six healthy volunteers developed life-threatening reactions. | NIBSC reports that trial material was identical to material used in preclinical work. Its follow-up found a dramatic response in a modified human-cell assay but not in the corresponding assay using monkey blood cells. | NIBSC’s institutional account illustrates a species-specific biological difference and the value of a human-cell assay. It does not establish that animal testing alone caused the trial outcome. |
| Fialuridine (FIAU), an antiviral nucleoside analog | Human trials revealed major hepatic or pancreatic toxicity that had not been anticipated from the animal studies. | The National Academies’ review found the animal studies comprehensive, but found no evidence in them from which the major human toxicity could have been anticipated. It also cautioned that one retrospective enzyme-change measure was not a valid measure of drug-induced liver toxicity. | The 1995 institutional review illustrates a translational limit and the difficulty of interpreting possible clinical signals. |
| BIA 10-2474, a FAAH inhibitor | A January 2016 first-in-human trial resulted in severe neurological harms and one death, according to a 2016 secondary review. | The evidence summarized here does not establish a definitive mechanism or independently verify detailed findings against the official investigation. | Keep the reported outcome separate from hypotheses about causation; the cited account is secondary. |
TGN1412: a human-cell response that monkey cells did not reproduce
NIBSC’s follow-up work found that a modified assay using human cells could reproduce the dramatic response, while the corresponding assay using monkey blood cells did not. NIBSC attributed the difference to subtle differences in how human and monkey white blood cells processed the drug. In NIBSC’s account of this specific drug, “for this drug, monkey studies would never predict the catastrophic reactions suffered by the human volunteers.” The organization says the work informed later European first-in-human trial regulations and new in-vitro assays.
A statement from the MHRA investigation, reproduced by Animal Research Information in an item dated April 5, 2006, put the mismatch this way: “In this case the resulting activity seen in humans was not predicted from apparently adequate pre-clinical testing.” Animal Research Information is reproducing the regulator’s statement, not itself the regulator.
Rank #2
FIAU: a signal is not automatically proof of toxicity
In its review of earlier FIAU patient studies, the National Academies committee reported that 24 of 79 patients across three studies had a peak-to-baseline AST or ALT increase greater than three at some point during therapy or follow-up. The committee explicitly said it did not consider that variable a valid measure of drug-induced hepatotoxicity. It should therefore not be described as 24 confirmed cases of drug-induced liver injury. The example shows why retrospective changes in a lab result need clinical interpretation rather than being treated as proof on their own.
BIA 10-2474: distinguish the reported harm from proposed explanations
The cited 2016 secondary review reports severe neurological harm and one death in the BIA 10-2474 trial. Because the evidence summarized here does not establish a definitive mechanism or independently confirm detailed findings against the official investigation, proposed explanations should not be presented as settled causes. The case supports a narrower point: a serious human-trial outcome does not, on its own, identify whether a model failed, a dose or monitoring decision contributed, or another factor was responsible.
Rank #3
What changes can make early drug testing more informative?
The FDA describes a weight-of-evidence approach that brings together different kinds of evidence rather than treating one animal study as a guarantee. It also discusses new approach methodologies, including human organ-on-chip systems, advanced in-vitro assays, computational modeling, and AI, as tools that may improve human-relevant insight. NIBSC’s TGN1412 account likewise describes the role of modified human-cell assays.
These approaches can address some limits of cross-species prediction, but the sources do not show that any single method guarantees a safe human trial. The FDA’s discussion describes a developing regulatory approach, not a claim that animal testing has already been replaced in all nonclinical drug studies. Trial safeguards and interpretation of the full evidence remain important even when more human-relevant methods are used.
Quick Recap
Best Value
- 2024 OSHA Construction Safety Book is the seventh edition with the new OSHA HazCom final rule on 5/20/24. While the rule takes effect 7/19/24, the compliance dates don’t begin until 1/19/26 per 29 CFR 1910.1200(j).
- Construction Site Book offers quick access to essential OSHA regulations, jobsite hazards, and practical safety tips. It also helps employees identify hazards and prevent injuries and illnesses.
- Features easy-to-read format, full-color images, chapter quizzes with answer key, and comes in a compact size making it a convenient reference for employees.
- Critical topics include Confined Space Entry; Cranes & Derricks; Electrical Safety; Emergency Response; Ergonomics & Back Safety; Excavations; Fall Protection; First Aid & Bloodborne Pathogens; HazCom; Health & Wellness; Jobsite Exposures; Lockout/Tagout; Ladders & Stairways; Materials Handling/Storage; Motor Vehicles; PPE; Scaffolds; Site Safety & Security; Slips, Trips & Falls; Tool Safety; Welding, Cutting & Brazing; and Work Zone Safety.
- Specifications: 5 1/4” x 7 1/4", English, Soft bound. 7th Edition. Copyright 2024.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Free tools Windows power users keep installed
One-click scans. No signup required.
